Lutris Pharma

Risk score

57
Large logo of Lutris Pharma

Headquarters

Flag of IsraelIsrael

Lutris-Pharma was founded with the aim of enhancing the effectiveness of anti-cancer treatment and improving the quality of life for patients receiving EGFR (Epidermal Growth Factor Receptor) Inhibitors or Radiation therapy. Dermal toxicity, a predominant adverse reaction of EGFR Inhibitors and Radiation therapy, is a limiting factor in cancer treatment compliance. Through the alleviation of this side effect, Lutris-Pharma facilitates continued and efficient EGFR Inhibitors and Radiation therapy.